Clinical Trial Results. org The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) Trial François Lespérance,

Slides:

Advertisements

Similar presentations

Effects of electroconvulsive therapy for depression on health related quality of life Adam Kavanagh.

Advertisements

A randomized controlled trial of citalopram on migraine frequency Satnam S. Nijjar, M.D. Department of Neurology, Johns Hopkins School of Medicine.

CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.

Clinical Trial Results. org Based on the Iron (Fe) and Atherosclerosis Study (FeAST) Leo R. Zacharski, MD; Bruce K. Chow, MS; Paula S. Howes, MS, APRN;

The ERICA Trial Peter H. Stone, MD, FACC, Nikolay A. Gratsiansky, MD, Alexey Blokhin, MD, I-Zu Huang, MD, Lixin Meng, MS, MPH, for the ERICA Investigators.

Mediators of Combined Cardiorespiratory Biofeedback and Dialectical Behavioral Skills Therapy for Treating Major Depressive Disorder and Low Heart Rate.

Clinical Trial Results. org Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for ST-Segment Myocardial Infarction: A Meta-Analysis.

Clinical Trial Results. org Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention.

Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

Differences in Patterns of Impairment, Psychiatric Comorbidity and Headache Beliefs in Migraine and Chronic Tension-type Headache Kathleen M. Romanek M.S.,

Effectiveness of a meditation-based stress management program as an adjunct to pharmacotherapy in patients with anxiety disorder Journal of Psychosomatic.

Clinical Trial Results. org The ERASE Trial: Effect of rHDL on Atherosclerosis-Safety and Efficacy Presented at American College of Cardiology Annual Scientific.

VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.

1 Statistical Perspective Acamprosate Experience Sue-Jane Wang, Ph.D. Statistics Leader Alcoholism Treatment Clinical Trials May 10, 2002 Drug Abuse Advisory.

Treatment for Adolescents With Depression Study (TADS)

Preventing Learned Helplessness In Depression Treatment Guideline Users Douglas E. Jorenby, Ph.D. Associate Professor 28 September 2005.

RESPONSE TO ANTIDEPRESSANT MEDICATION, COGNITIVE BEHAVIOR THERAPY AND PLACEBO IN CHRONIC TENSION-TYPE HEADACHE VARIES WITH PSYCHIATRIC COMORBIDITY & HEADACHE.

Antidepressants and Suicidality in Adults: Statistical Evaluation Mark Levenson, Ph.D.* and Chris Holland, M.S. Statistical Safety Reviewers Quantitative.

Effect of Depression on Smoking Cessation Outcomes Sonne SC 1, Nunes EV 2, Jiang H 2, Gan W 2, Tyson C 1, Reid MS 3 1 Medical University of South Carolina,

BARI 2D Trial BARI 2D Trial Presented at the American Diabetes Association (ADA) Annual Scientific Sessions 2009 in New Orleans The Bypass Angioplasty.

The Effectiveness of Psychodynamic Therapy and Cognitive Behavior Therapy in the Treatment of Personality Disorders: A Meta-Analysis. By Falk Leichsenring,

Mindfulness as Predictor of Treatment Outcome in Cognitive Behavioral and Acceptance and Commitment Therapies Ethan Moitra, Maria del Mar Cabiya, Evan.

Interferences between depression and life quality on patients suffering of type 2 diabetes First Author : Madalina Crisan Coauthors: Madalina Salagean.

A Randomized Placebo- Controlled Trial of Metformin for the Treatment of HIV Lipodystrophy Rakhi Kohli MD MS, Christine Wanke MD, Sherwood Gorbach MD,

Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.

Depression and Parkinson Disease: An Old Drug Still Works (Better) Summary and Comment by Jonathan Silver, MD Published in Journal Watch Psychiatry February.

Scandinavian Simvastatin Survival Study (4S) The Lancet, Vol 344, November 19, 1994.

Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction Benjamin M. Scirica, MD, MPH On behalf of the TRA 2°P-TIMI 50 Steering.

Published in Circulation 2003 Rory Hachamovitch, MD, MSc; Sean W. Hayes, MD; John D. Friedman, MD; Ishac Cohen PhD; Daniel S. Berman, MD Comparison of.

Clinical Trial Results. org SAGE Trial Prakash Deedwania, MD; Peter H. Stone, MD; C. Noel Bairey Merz, MD; Juan Cosin-Aguilar, MD; Nevres Koylan, MD; Don.

Do Instrumental Activities of Daily Living Predict Dementia at 1- and 2- Year Follow-Up? Findings from the Development of Screening Guidelines and Diagnostic.

FDA Hearing on Suicide and Antidepressants Presentation by Charles F. Reynolds, III, MD UPMC Professor of Geriatric Psychiatry University of Pittsburgh.

HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.

Sertraline Use in Pediatric Population: A Risk Benefit Discussion Steven J. Romano, MD September 13, 2004 Steven J. Romano, MD September 13, 2004 Joint.

STAR*D Objectives Compare relative efficacy of different treatment options –Goal is REMISSION, not just “response” –Less than half of patients with depression.

Clinical Trial Results. org Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity.

Relational Discord at Conclusion of Treatment Predicts Future Substance Use for Partnered Patients Wayne H. Denton, MD, PhD; Paul A. Nakonezny, PhD; Bryon.

Effectiveness of Cognitive Behavioral Therapy and Selective Serotonin Reuptake Inhibitors in Adolescents with Depression Megan Boose, PA-S Evidence Based.

Effects of Initial Dosing Strategies of Duloxetine on Tolerability and Efficacy in Patients with Major Depressive Disorder David Dunner, MD 1 (sponsor);

Clinical Trial Results. org METEOR Trial Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. John R.

CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.

Augmentation of Exposure-Based Cognitive Behavioral Therapy with D-cycloserine in Patients with Panic Disorder Sean Donovan, Meenakshi Shelat, Corrinne.

FRagmin® and Fast Revascularization during InStablity in Coronary artery disease FRISC II.

Clinical Trial Results. org RAAVE Luis M. Moura, MD; Sandra F. Ramos, MSc; José L. Zamorano, MD, PhD; Isabel M. Barros, MD; Luis F. Azevedo, MD; Francisco.

HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.

European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.

Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.

Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.

Intravenous Erythropoietin in Patients with ST-Segment Elevation MI -- Study performed by: Najjar et al -- Presented by: Jay Hall PA-SII, Ali Rahimi MD.

LSU Journal Club Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD WISDOM study H. Magnussen MD, et al. Nisha Loganantharaj, PGY1 April 21,

Randomized Controlled CTN Trial of OROS-MPH + CBT in Adolescents with ADHD and Substance Use Disorders Paula Riggs, M.D., Theresa Winhusen, PhD., Jeff.

Table 2. Characterization of the Pubmed data base’s articles included in the sample Selene Cordeiro Vasconcelos et al. Psychiatrics Disorders in Crack.

Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.

Clinical Trial Results. org Impact of Epicardial Anterior Fat Pad Retention on Postcardiothoracic Surgery Atrial Fibrillation Incidence: The AFIST-III.

Clinical Trial Results. org ILLUSTRATE Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. Steven E.

Association of Cognitive Outcomes and Response Status in Late Life Depression: A 12 Month Longitudinal Study David Bickford B.A., Alana Kivowitz B.A.,

CoRPS Center of Research on Psychology in Somatic diseases Brief Depression Screening with the PHQ-2 Predicts Poor Prognosis following PCI with Drug-Eluting.

Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results Stephen G. Ellis, MD,

Transcranial direct current stimulation (tDCS) in therapy-resistant depression: Preliminary results from a double-blind, placebo-controlled study. U. Palm,

Pharmacological and Behavioral

Mean Responses on PGI-Improvement Primary Endpoint at Week 12

Efficacy of Paroxetine (Paxil) in the Treatment of Adolescent Major Depression: A Randomized, Controlled Trial Case Study presented by: carlo carandang,

The numbered points represent individual studies

Scandinavian Simvastatin Survival Study (4S)

Ranolazine in Microvascular Dysfunction

Fig. 1. MAHALO clinical trial flowchart.

Stephen J. Nicholls, MBBS, PhD; E

The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter

Presentation transcript:

Clinical Trial Results. org The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) Trial François Lespérance, MD; Nancy Frasure-Smith, PhD; Diana Koszycki, PhD; Marc-André Laliberté, MD; Louis T. van Zyl, MD; Brian Baker, MBChB; John Robert Swenson, MD; Kayhan Ghatavi, MD; Beth L. Abramson, MD; Paul Dorian, MD; Marie-Claude Guertin, PhD; for the CREATE Investigators Published in JAMA, January 24, 2007 Effects of Citalopram and Interpersonal Psychotherapy on Depression in Patients with Coronary Artery Disease

Clinical Trial Results. org CREATE Trial: Background Few randomized controlled trials have evaluated the efficacy of treatments for major depression patients with coronary artery disease (CAD).Few randomized controlled trials have evaluated the efficacy of treatments for major depression patients with coronary artery disease (CAD). No previous studies have simultaneously evaluated an antidepressant and short-term psychotherapy.No previous studies have simultaneously evaluated an antidepressant and short-term psychotherapy. Few randomized controlled trials have evaluated the efficacy of treatments for major depression patients with coronary artery disease (CAD).Few randomized controlled trials have evaluated the efficacy of treatments for major depression patients with coronary artery disease (CAD). No previous studies have simultaneously evaluated an antidepressant and short-term psychotherapy.No previous studies have simultaneously evaluated an antidepressant and short-term psychotherapy. Lespérance et al., JAMA 2007; 297(4):

Clinical Trial Results. org CREATE Trial: Background Cont. CREATE is the first trial specifically designed to evaluate the short-term efficacy and tolerability of 2 depression treatments in patients with CAD: citalopram, a selective serotonin reuptake inhibitor (SSRI), and interpersonal psychotherapy (IPT), a short- term, manual-based psychotherapy focusing on the social context of depression.CREATE is the first trial specifically designed to evaluate the short-term efficacy and tolerability of 2 depression treatments in patients with CAD: citalopram, a selective serotonin reuptake inhibitor (SSRI), and interpersonal psychotherapy (IPT), a short- term, manual-based psychotherapy focusing on the social context of depression. Lespérance et al., JAMA 2007; 297(4):

Clinical Trial Results. org Clinical Management Only n=142 Clinical Management Only n=142 Clinical Management + IPT n=142 Clinical Management + IPT n=142 CREATE Trial: Study Design Citalopram n=67 Placebo n= Patients with CAD from 9 Canadian academic centers, meeting the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for major depression > 4 weeks duration and had baseline 24-item Hamilton Depression Rating Scale (HAM-D) > 20 2X2 Factorial. Randomized. Controlled. Parallel-Group. Double-blinded. Mean age 58.2 years, 25% women 284 Patients with CAD from 9 Canadian academic centers, meeting the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for major depression > 4 weeks duration and had baseline 24-item Hamilton Depression Rating Scale (HAM-D) > 20 2X2 Factorial. Randomized. Controlled. Parallel-Group. Double-blinded. Mean age 58.2 years, 25% women  Primary Endpoint Change in 24-item HAM-D from baseline.  Secondary Endpoint: Self-reported Beck Depression Inventory II (BDI- II) score  Primary Endpoint Change in 24-item HAM-D from baseline.  Secondary Endpoint: Self-reported Beck Depression Inventory II (BDI- II) score 12 weeks R R R Citalopram n=75 Placebo n=67 Lespérance et al., JAMA 2007; 297(4):

Clinical Trial Results. org CREATE Trial: Baseline Characteristics Characteristics IPT + Citalopram (n=67) IPT + Placebo (n=75) Clinical Management + Citalopram (n= 75) Clinical Management + Placebo (n=67) Age, mean (SD), yr 58.6 (10.44) 59.4 (9.28) 57.3 (7.83) 57.3 (8.95) Female, n (%) 26 (38.8) 18 (24.0) 7 (9.3) 19 (28.4) Previous MI, n (%) 40 (59.7) 54 (72.0) 49 (65.3) 41 (61.2) HAM-D-24 score, mean (SD) 28.8 (6.39) 30.0 (6.43) 29.6 (6.43) 30.3 (7.64) BDI-II score, mean (SD) 30.2 (8.85) 29.4 (9.83) 30.4 (9.27) 31.3 (9.34) Recurrent Depression, n (%) 33 (49.3) 42 (56.0) 34 (45.3) 27 (40.3) Lespérance et al., JAMA 2007; 297(4):

Clinical Trial Results. org Citalopram was superior in reducing 12-week HAM-D scores (mean difference=3.3 points, p=0.005) vs. placebo.Citalopram was superior in reducing 12-week HAM-D scores (mean difference=3.3 points, p=0.005) vs. placebo. There was no significant difference in mean HAM-D scores for clinical management vs. IPT.There was no significant difference in mean HAM-D scores for clinical management vs. IPT. 24-item HAM-D score (mean) CREATE Trial: Primary Endpoint n = 142 p = item HAM-D score at follow up for Citalopram vs. Placebo Lespérance et al., JAMA 2007; 297(4):

Clinical Trial Results. org Citalopram was superior in reducing BDI-II scores (mean difference=3.6 points, p=0.005) vs. placebo.Citalopram was superior in reducing BDI-II scores (mean difference=3.6 points, p=0.005) vs. placebo. There was no significant difference in BDI-II scores for clinical management vs. IPT.There was no significant difference in BDI-II scores for clinical management vs. IPT. BDI-II score (mean) CREATE Trial: Secondary Endpoint n = 142 p = BDI-II score at follow up for Citalopram vs. Placebo Lespérance et al., JAMA 2007; 297(4):

Clinical Trial Results. org CREATE Trial: Limitations Recruitment of participants through advertisements and exclusion of those unwilling to accept randomization, both of which reduced the generalizability of results.Recruitment of participants through advertisements and exclusion of those unwilling to accept randomization, both of which reduced the generalizability of results. Even though most analyses were preplanned, some significant differences may have occurred by chance.Even though most analyses were preplanned, some significant differences may have occurred by chance. Recruitment of participants through advertisements and exclusion of those unwilling to accept randomization, both of which reduced the generalizability of results.Recruitment of participants through advertisements and exclusion of those unwilling to accept randomization, both of which reduced the generalizability of results. Even though most analyses were preplanned, some significant differences may have occurred by chance.Even though most analyses were preplanned, some significant differences may have occurred by chance. Lespérance et al., JAMA 2007; 297(4):

Clinical Trial Results. org CREATE Trial: Limitations Cont. By chance, more women were randomized to receive IPT than clinical management alone; however, there was no difference between men and women in their responses to citalopram/placebo or IPT/clinical management.By chance, more women were randomized to receive IPT than clinical management alone; however, there was no difference between men and women in their responses to citalopram/placebo or IPT/clinical management. Lespérance et al., JAMA 2007; 297(4):

Clinical Trial Results. org CREATE Trial: Summary CREATE trial documents the efficacy of citalopram administered in conjunction with weekly clinical management for patients with CAD.CREATE trial documents the efficacy of citalopram administered in conjunction with weekly clinical management for patients with CAD. There is, however, no evidence of added value of IPT over clinical management.There is, however, no evidence of added value of IPT over clinical management. CREATE trial documents the efficacy of citalopram administered in conjunction with weekly clinical management for patients with CAD.CREATE trial documents the efficacy of citalopram administered in conjunction with weekly clinical management for patients with CAD. There is, however, no evidence of added value of IPT over clinical management.There is, however, no evidence of added value of IPT over clinical management. Lespérance et al., JAMA 2007; 297(4):

Clinical Trial Results. org CREATE Trial: Summary Based on this trial and previous studies, citalopram or sertraline in addition to clinical management should be considered as a first- step treatment for patients with CAD and major depression.Based on this trial and previous studies, citalopram or sertraline in addition to clinical management should be considered as a first- step treatment for patients with CAD and major depression. Lespérance et al., JAMA 2007; 297(4):